Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Dapagliflozin

Brand: Forxiga®
NICE TA: 288
Indication: In combination therapy for treating type 2 diabetes (NICE TA288)
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

Dapagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:
1. a sulfonylurea is contraindicated or not tolerated or
2. the person is at significant risk of hypoglycaemia or its consequences.
Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.
The third recommendation, previously part of this guidance, has been updated and replaced by NICE’s technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
The LMMG recommends dapagliflozin as a 1st line ““gliflozin””.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Green

Green (Restricted)

Green (Restricted)

Green (restricted)

Green

Green (Restricted)